pCPA Activity Overview
Status | Total Negotiations | Summary |
---|---|---|
Active Negotiations | 44 | Non-oncology: 27 Oncology: 17 |
Under Consideration for Negotiation | 15 | Non-oncology: 12 Oncology: 3 |
Completed Negotiations | 780 | With Letter of Intent: 674 Without agreement: 106 |
Negotiations That Were Not Pursued | 108 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
Brand Name | Manufacturer | Indication | Engagement Date |
---|---|---|---|
Ofev | Boehringer Ingelheim (Canada) Ltd. | Idiopathic pulmonary fibrosis and PF-ILD | |
Ojjaara | GlaxoSmithKline Inc. | For the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary myelofibrosis (MF), post polycythemia vera myelofibrosis or post essential thrombocythemia MF who have moderate to severe anemia. | |
Balversa | Janssen Inc. | Adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior th | |
Vabysmo | Hoffmann-La Roche Ltd. | Retinal vein occlusion | |
Filra | Jamp Pharma Corporation | Multiple Indications | |
Niopeg | Nora Pharma Inc. | To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug. | |
Breyanzi | Bristol Myers Squibb Canada Inc. | Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL), and DLBCL arising from follicular lymphoma, who have refractory di | |
Cosentyx | Novartis Pharmaceuticals Canada Inc. | Hidradenitis Suppurativa |